OPEN ACCESS: All - Clare Dyer
- 1BMJ
The US Supreme Court has ruled as invalid two patents on a test that helps doctors determine drug dosage for autoimmune disorders such as Crohn’s disease, in a landmark decision that will affect the growing field of personalised medicine.
The justices ruled unanimously that patents on a test developed by Prometheus Laboratories were invalid because they were based on the laws of nature.
The test was designed to find out the level of thiopurine that should be administered to an individual patient: too much might be toxic, …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
PDF
Social bookmarking